Literature DB >> 11390328

Steroids and risk of upper gastrointestinal complications.

S Hernández-Díaz1, L A Rodríguez.   

Abstract

Most antiinflammatory drugs have been associated with an increase in upper gastrointestinal complications. However, the literature on steroids is more limited than that on nonsteroidal antiinflammatory drugs (NSAIDs). To estimate the risk of upper gastrointestinal complications associated with use of steroids alone and in combination, a nested case-control analysis was conducted on the General Practice Research Database from the United KINGDOM: The authors identified 2,105 cases of upper gastrointestinal complications and 11,500 controls between 1993 and 1998. The adjusted odds ratios associated with current use of oral steroids were 1.8 (95% confidence interval (CI): 1.3, 2.4) for upper gastrointestinal complications overall and 2.4 (95% CI: 1.7, 3.4) for gastric and 1.2 (95% CI: 0.8, 1.9) for duodenal damage. Steroids were similarly associated with bleeding (odds ratio (OR) = 1.8; 95% CI: 1.3, 2.4) and perforations (OR = 1.6; 95% CI: 0.9, 3.1). Simultaneous use of steroids with low-medium and high NSAID doses, respectively, produced odds ratios of 4.0 (95% CI: 1.3, 12.0) and 12.7 (95% CI: 6.2, 26.1), compared with users of none. Whenever possible, antiinflammatory drugs should be given in monotherapy and at the lowest effective dose in order to reduce the risk of upper gastrointestinal complications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390328     DOI: 10.1093/aje/153.11.1089

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  25 in total

1.  Factors associated with the initiation of proton pump inhibitors in corticosteroid users.

Authors:  Jeffrey C Munson; Peter M Wahl; Gregory Daniel; Stephen E Kimmel; Sean Hennessy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01-25       Impact factor: 2.890

Review 2.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Intravenous lidocaine for effective pain relief after bimaxillary surgery.

Authors:  Uilyong Lee; Young-Jun Choi; Geun Joo Choi; Hyun Kang
Journal:  Clin Oral Investig       Date:  2017-02-06       Impact factor: 3.573

4.  Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation.

Authors:  David Y Graham; Nicholas P Jewell; Francis K L Chan
Journal:  Am J Med Sci       Date:  2011-11       Impact factor: 2.378

Review 5.  A benefit-risk assessment of the use of proton pump inhibitors in the elderly.

Authors:  Gwen M C Masclee; Miriam C J M Sturkenboom; Ernst J Kuipers
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

6.  Another 'Cushing ulcer'.

Authors:  Chisho Hoshino; Noriyuki Satoh; Masashi Narita; Akio Kikuchi; Minoru Inoue
Journal:  BMJ Case Rep       Date:  2011-04-09

7.  Risk of adverse gastrointestinal events from inhaled corticosteroids.

Authors:  Richard A Hansen; Wanzhu Tu; Jane Wang; Roberta Ambuehl; Clement J McDonald; Michael D Murray
Journal:  Pharmacotherapy       Date:  2008-11       Impact factor: 4.705

8.  Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?

Authors:  G M C Masclee; V E Valkhoff; E M van Soest; R Schade; G Mazzaglia; M Molokhia; G Trifirò; J L Goldstein; S Hernández-Díaz; E J Kuipers; M C J M Sturkenboom
Journal:  Aliment Pharmacol Ther       Date:  2013-05-28       Impact factor: 8.171

Review 9.  Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection.

Authors:  Ying-Chun Lo; Chen-Fang Lee; Jonathan D Powell
Journal:  Curr Opin Organ Transplant       Date:  2014-08       Impact factor: 2.640

10.  Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy.

Authors:  Jiing-Chyuan Luo; Full-Young Chang; Tseng-Shing Chen; Yee-Yung Ng; Han-Chieh Lin; Ching-Liang Lu; Chih-Yen Chen; Hsiao-Yi Lin; Shou-Dong Lee
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.